BorjeS.AnderssonMD

PubMed

• 69 citations
  T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.
  Apostolia Maria Tsimberidou, Karlyle Van Morris, Henry Hiep Vo, Stephen Eck, Yu Feng Lin
  Journal of Hematology & Oncology. 2021-06-30
• 47 citations
  Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia
  Piyanuch Kongtim, Uday R. Popat, Antonio M. Jimenez, Sameh Gaballa, Riad El Fakih
  Biology of Blood and Marrow Transplantation. 2016-01-01
• 755 citations
  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatmen...
  Issa F. Khouri, Michael J. Keating, M. Korbling, Donna Przepiorka, Paolo Anderlini
  Journal of Clinical Oncology. 1998-08-01

Journal Articles

• Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...  
  Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature

Abstracts/Posters

• Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell ...
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study
  Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018